AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Adaptimmune Therapeutics Plc (NASDAQ:ADAP)
0.252 USD
+0.010 3.960%| Previous Close (in USD) | 0.2424 |
|---|---|
| Change | +0.010 3.960% |
| 52 W H/L (in USD) | 2.050/0.430 |
| EBITDA (in USD) | -72.88M |
| PE Ratio | -- |
| Volume | 237755 |
| Diluted Eps TTM | -0.17 |
| Total Assets (in USD) | 282.616M |
|---|---|
| Total Liabilities (in USD) | 243.103M |
| Revenue TTM (in USD) | 141.459M |
| Cash (in USD) | 143.991M |
| Market Cap (in USD) | 160.208 M |
| Revenue Per Share TTM | 0.595 |
| Gross Profit TTM (in USD) | -100.578M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees: 449
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 1972 |
| 2. | Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder & Chief Bus. & Strategy Officer | 1967 |
| 3. | Mr. Gavin Hilary James Wood BA (Hons), ACA | Chief Financial Officer | 1970 |
| 4. | Mr. William C. Bertrand Jr., Esq., J.D. | Chief Operating Officer | 1965 |
| 5. | Mr. John Lunger | Chief Patient Supply Officer | 1969 |
| 6. | Ms. Joanna Brewer Ph.D. | Chief Scientific Officer | NA |
| 7. | Dr. Juli P. Miller Ph.D. | VP of Investor Relations | NA |
| 8. | Ms. Kerry Sharp | Sr. VP & Gen. Council | NA |
| 9. | Ms. Margaret Henry | Head of PR & Company Sec. | NA |
| 10. | Mr. Sébastien Desprez | VP of Communications & Corp. Affairs | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.850 1.219% | 70.245 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.320 1.881% | 71.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.035 1.135% | 445 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+13.950 2.725% | 515.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -112.535M | -162.959M | -157.299M | -129.93M | -136.923M |
| Minority Interest | - | - | - | - | - |
| Net Income | -113.871M | -165.456M | -158.09M | -130.092M | -137.165M |
| Selling General Administrative | 71.81M | 63.387M | 57.305M | 45.795M | 43.391M |
| Gross Profit | 50.424M | -100.578M | -104.941M | -87.61M | -96.379M |
| Reconciled Depreciation | 9.84M | 6.075M | 6.567M | 7.594M | 8.01M |
| Ebit | -138.038M | -161.664M | -162.245M | -133.464M | -139.77M |
| Ebitda | -128.198M | -155.593M | -155.679M | -125.811M | -131.76M |
| Depreciation And Amortization | 9.84M | 6.071M | 6.566M | 7.653M | 8.01M |
| Operating Income | -138.038M | -163.965M | -162.246M | -133.405M | -139.77M |
| Other Operating Expenses | 198.281M | 191.113M | 168.395M | 137.363M | 140.892M |
| Interest Expense | - | 1.006M | 4.947M | 3.475M | 2.847M |
| Tax Provision | 1.336M | 2.497M | 0.791M | 0.162M | 0.242M |
| Interest Income | 5.964M | 1.542M | 1.095M | 2.313M | 2.772M |
| Net Interest Income | 5.964M | 1.542M | 1.095M | 2.313M | 2.772M |
| Income Tax Expense | 1.336M | 2.497M | 0.791M | 0.162M | 0.242M |
| Total Revenue | 60.281M | 27.148M | 6.149M | 3.958M | 1.122M |
| Total Operating Expenses | 200.022M | 191.113M | 168.395M | 137.363M | 140.892M |
| Cost Of Revenue | 9.857M | 127.726M | 111.09M | 91.568M | 97.501M |
| Total Other Income Expense Net | 25.503M | -1.291M | 4.947M | 3.475M | 2.847M |
| Net Income From Continuing Ops | -113.871M | -165.456M | -158.09M | -130.092M | -137.165M |
| Net Income Applicable To Common Shares | - | -165.456M | -158.09M | -130.092M | -137.165M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 282.616M | 328.916M | 469.545M | 451.142M | 181.543M |
| Intangible Assets | 0.33M | 0.442M | 1M | 1.73M | 2.198M |
| Other Current Assets | 13.695M | 43.33M | 45.126M | 29.796M | 30.947M |
| Total Liab | 243.103M | 247.038M | 263.585M | 109.915M | 57.905M |
| Total Stockholder Equity | 39.513M | 81.878M | 205.96M | 341.227M | 123.638M |
| Other Current Liab | 30.303M | 33.5M | 29.909M | 27.079M | 23.363M |
| Common Stock | 1.865M | 1.399M | 1.337M | 1.325M | 0.943M |
| Capital Stock | 1.865M | 1.399M | 1.337M | 1.325M | 0.943M |
| Retained Earnings | -1023.173M | -909.302M | -743.846M | -585.756M | -455.664M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 1.569M | 1.718M | 4.602M | 6.999M |
| Cash | 143.991M | 108.033M | 149.948M | 56.882M | 50.412M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 72.788M | 64.501M | 62.541M | 39.073M | 34.341M |
| Current Deferred Revenue | 28.973M | 23.52M | 22.199M | 2.832M | 2.128M |
| Net Debt | -118.756M | -84.956M | -124.48M | -33.171M | -24.953M |
| Short Term Debt | 5.384M | 2.728M | 2.32M | 2.773M | 2.493M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 25.235M | 23.077M | 25.468M | 23.711M | 25.459M |
| Other Stockholder Equity | 1064.569M | 990.656M | 959.611M | 935.706M | 585.623M |
| Property Plant Equipment | - | 71.535M | 30.494M | 27.778M | 31.068M |
| Total Current Assets | 207.552M | 255.37M | 415.458M | 398.152M | 120.489M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 2.947M | 96.572M | 219.632M | 311.335M | 39.13M |
| Net Receivables | 46.919M | 7.435M | 0.752M | 0.139M | -1.459M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 1.329M | 1.279M | 0.746M | 2.086M | 1.459M |
| Accounts Payable | 8.128M | 4.753M | 8.113M | 6.389M | 6.357M |
| Accumulated Other Comprehensive Income | -3.748M | -0.875M | -11.142M | -10.048M | -7.264M |
| Non Currrent Assets Other | 3.026M | 1.569M | 1.718M | 4.602M | 6.999M |
| Non Current Assets Total | 75.064M | 73.546M | 54.087M | 52.99M | 61.054M |
| Capital Lease Obligations | 25.235M | 23.077M | 25.468M | 23.711M | 25.459M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | 176.538M | 89.137M | 84.581M | -276.018M | 98.019M |
| Total Cashflows From Investing Activities | - | 89.137M | 75.8M | -278.924M | 94.945M |
| Total Cash From Financing Activities | 0.88M | 12.867M | 3.288M | 340.051M | 0.366M |
| Net Income | -113.871M | -165.456M | -158.09M | -130.092M | -137.165M |
| Change In Cash | 37.415M | -42.064M | 90.182M | 6.576M | -17.568M |
| Begin Period Cash Flow | 109.602M | 151.666M | 61.484M | 54.908M | 72.476M |
| End Period Cash Flow | 147.017M | 109.602M | 151.666M | 61.484M | 54.908M |
| Total Cash From Operating Activities | -140.88M | -141.769M | 10.729M | -53.591M | -112.507M |
| Depreciation | 9.453M | 6.075M | 6.567M | 7.594M | 8.01M |
| Other Cashflows From Investing Activities | - | - | -0.207M | -0.565M | -1.482M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0M | 5.402M | 15.149M | -5.658M | -6.193M |
| Sale Purchase Of Stock | - | - | 3.288M | 340.051M | 0.366M |
| Other Cashflows From Financing Activities | 0.256M | 0.05M | 0.759M | 5.663M | -0.002M |
| Capital Expenditures | 4.88M | 29.74M | 8.781M | 2.906M | 3.074M |
| Change In Working Capital | -25.049M | -1.531M | 134.634M | 56.045M | 4.717M |
| Other Non Cash Items | -23.186M | 0.903M | 1.173M | -0.055M | -0.185M |
| Free Cash Flow | -145.76M | -171.509M | 1.948M | -56.497M | -115.581M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Edinburgh Worldwide Ord | 9 months ago | 7456308 |
| 2. | Baillie Gifford Global Discovery A Acc | 7 months ago | 3322172 |
| 3. | Baillie Gifford WW Discovery B USD Acc | 7 months ago | 1622277 |
| 4. | JPM Thematics Genetic Thrps C2 Acc USD | 7 months ago | 939248 |
| 5. | Galileo - Biotech Innovation Fund S USD | 1 year ago | 752458 |
| 6. | Mercer Global Small Cap Equity M-5£ | 7 months ago | 484782 |
| 7. | SPDR® Portfolio Developed Wld ex-US ETF | 6 months ago | 251080 |
| 8. | Fidelity Enhanced Small Cap ETF | 6 months ago | 177827 |
| 9. | SEI International Equity F (SIT) | 6 months ago | 175243 |
| 10. | SPDR® S&P® International Small Cap ETF | 6 months ago | 146899 |
| 11. | Fidelity Nasdaq Composite Index | 7 months ago | 139801 |
| 12. | Top Class Healthcare FI | 7 months ago | 75000 |
| 13. | Club Innovation Santé | 6 months ago | 45351 |
| 14. | Invesco NASDAQ Future Gen 200 ETF | 6 months ago | 34809 |
| 15. | Northern Small Cap Core I | 8 months ago | 16891 |
| 16. | NT Quality SCC US Fund - L | 11 months ago | 10076 |
| 17. | NT Quality Small Cap Core | 8 months ago | 9548 |
| 18. | Palisades AlphaQ Small Growth | 8 months ago | 7328 |
| 19. | Baillie Gifford US Discovery Instl | 8 months ago | 6385 |
| 20. | Baillie Gifford US Discovery Fund | 7 months ago | 6385 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | MPM Oncology Impact Management LP | 8 months ago | 5095912 |
| 2. | Bank of America Corp | 8 months ago | 4653325 |
| 3. | Rock Springs Capital Management LP | 8 months ago | 2425468 |
| 4. | Morgan Stanley - Brokerage Accounts | 8 months ago | 1699025 |
| 5. | Renaissance Technologies Corp | 8 months ago | 1656575 |
| 6. | JPMorgan Chase & Co | 8 months ago | 1045533 |
| 7. | Redmile Group, LLC | 8 months ago | 715607 |
| 8. | Millennium Management LLC | 8 months ago | 715350 |
| 9. | Marshall Wace Asset Management Ltd | 8 months ago | 522608 |
| 10. | Rathbone Brothers PLC | 8 months ago | 432818 |
| 11. | State Street Corp | 8 months ago | 396792 |
| 12. | Dafna Capital Management LLC | 8 months ago | 341064 |
| 13. | Matrix Capital Management Company, LLC | 8 months ago | 37681515 |
| 14. | EcoR1 Capital, LLC | 8 months ago | 27404070 |
| 15. | NEA Management Company, LLC | 8 months ago | 17079778 |
| 16. | Baillie Gifford & Co Limited. | 8 months ago | 16775860 |
| 17. | Long Focus Capital Management, LLC | 8 months ago | 13299890 |
| 18. | Partner Fund Management LP | 8 months ago | 10000787 |
| 19. | Mpm Asset Management, LLC | 8 months ago | 5555461 |
| 20. | FMR Inc | 8 months ago | 1740900 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...